Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Leuk Lymphoma ; 60(13): 3161-3171, 2019 12.
Article in English | MEDLINE | ID: mdl-31111762

ABSTRACT

Myelodysplastic syndromes (MDS), a spectrum of heterogeneous hematopoietic stem cell diseases, vary in clinical severity, response to therapy, and propensity toward progression to acute myeloid leukemia. These are acquired clonal disorders resulting from somatic mutations within the hematopoietic stem or progenitor cell population. Understanding the natural history and the risk of developing leukemia and other adverse outcomes is dependent on access to well-annotated biospecimens linked to robust clinical and molecular data. To facilitate the acquisition and distribution of MDS biospecimens to the wider scientific community and support scientific discovery in this disease, the National MDS Natural History study was initiated by the National Heart, Lung, and Blood Institute (NHLBI) and is being conducted in collaboration with community hospitals and academic medical centers supported by the National Cancer Institute (NCI). The study will recruit up to 2000 MDS patients or overlapping myeloproliferative neoplasms (MDS/MPN) and up to 500 cases of idiopathic cytopenia of undetermined significance (ICUS). The National MDS Natural History Study (NCT02775383) will offer the world's largest disease-focused tissue biobank linked to longitudinal clinical and molecular data in MDS. Here, we report on the study design features and describe the vanguard phase of 200 cases. The study assembles a comprehensive clinical database, quality of life results, laboratory data, histopathology slides and images, genetic information, hematopoietic and germline tissues representing high-quality biospecimens and data from diverse centers across the United States. These resources will be available to the scientific community for investigator-initiated research.


Subject(s)
Biological Specimen Banks/organization & administration , Biomedical Research/organization & administration , Cytogenetic Analysis , Myelodysplastic Syndromes/pathology , Adult , Aged , Aged, 80 and over , Biological Specimen Banks/economics , Biomedical Research/economics , Female , Humans , Male , Middle Aged , Mutation , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/genetics , National Cancer Institute (U.S.)/economics , National Cancer Institute (U.S.)/organization & administration , National Heart, Lung, and Blood Institute (U.S.)/economics , National Heart, Lung, and Blood Institute (U.S.)/organization & administration , Observational Studies as Topic , Research Design , United States , Young Adult
2.
Liver Transpl ; 23(6): 762-768, 2017 06.
Article in English | MEDLINE | ID: mdl-27935212

ABSTRACT

Hepatitis C virus (HCV) infection is the leading cause of liver disease in hemophilia patients. In those with human immunodeficiency virus (HIV)/HCV coinfection, the rate of liver disease progression is greater than in HCV monoinfected individuals. Despite antiretroviral therapy, which slows HCV liver disease progression, some require transplantation. Whether transplant outcomes are worse in hemophilic (H) rather than nonhemophilic (NH) candidates is unknown. In order to determine rates and predictors of pretransplant and posttransplant survival, we conducted a retrospective observational study using United Network for Organ Sharing national transplant registry data, comparing HCV+ H and NH candidates. We identified 2502 HCV+ liver transplant candidates from 8 US university-based transplant centers, between January 1, 2004 to December 31, 2010, including 144 HIV+ (6%) and 2358 HIV-; 36 H (1%) and 2466 NH; 1213 (48%) transplanted and 1289 not transplanted. Other than male predominance and younger age, each were P < 0.001. Baseline data were comparable between H and NH. In univariate analysis, 90-day pretransplant mortality was associated with higher baseline Model for End-Stage Liver Disease (MELD; hazard ratio [HR] = 1.15; P < 0.001), lower baseline platelet count (HR = 0.9 per 25,000/µL; P = 0.04), and having HIV/HCV+ hemophilia (P = 0.003). In multivariate analysis, pretransplant mortality was associated with higher MELD (P < 0.001) and was significantly greater in HIV+ than HIV- groups (P = 0.001). However, it did not differ between HIV+ H and NH (HR = 1.7; P = 0.36). Among HIV/HCV+, posttransplant mortality was similar between H and NH, despite lower CD4 in H (P = 0.04). In conclusion, this observational study confirms that hemophilia per se does not have a specific influence on transplant outcomes and that HIV infection increases the risk of mortality in both H and NH patients. Liver Transplantation 23 762-768 2017 AASLD.


Subject(s)
HIV Infections/surgery , Hemophilia A/surgery , Hepatitis C, Chronic/surgery , Liver Failure/surgery , Liver Transplantation , Adult , Anti-Retroviral Agents/therapeutic use , CD4-Positive T-Lymphocytes/cytology , Coinfection/mortality , Data Interpretation, Statistical , Disease Progression , Female , HIV Infections/complications , HIV Infections/mortality , Hemophilia A/complications , Hemophilia A/mortality , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/mortality , Humans , Liver Failure/complications , Liver Failure/mortality , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Postoperative Complications , Registries , Retrospective Studies , Time Factors , Treatment Outcome , United States
4.
J Immunol ; 197(7): 2726-37, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27591322

ABSTRACT

The recombinant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acquisition. Ab responses to the V1/V2 regions have correlated with a decreased risk of virus acquisition in both humans and macaques. We hypothesized that the breadth and functional profile of Abs induced by an ALVAC/envelope protein regimen could be improved by substituting the monomeric gp120 boost, with the full-length single-chain (FLSC) protein. FLSC is a CD4-gp120 fusion immunogen that exposes cryptic gp120 epitopes to the immune system. We compared the immunogenicity and relative efficiency of an ALVAC-SIV vaccine boosted either with bivalent FLSC proteins or with monomeric gp120 in alum. FLSC was superior to monomeric gp120 in directing Abs to the C3 α2 helix, the V5 loop, and the V3 region that contains the putative CCR5 binding site. In addition, FLSC boosting elicited significantly higher binding Abs to V2 and increased both the Ab-dependent cellular cytotoxicity activity and the breadth of neutralizing Abs. However, the FLSC vaccine regimen demonstrated only a trend in vaccine efficacy, whereas the monomeric gp120 regimen significantly decreased the risk of SIVmac251 acquisition. In both vaccine regimens, anti-V2 Abs correlated with a decreased risk of virus acquisition but differed with regard to systemic or mucosal origin. In the FLSC regimen, serum Abs to V2 correlated, whereas in the monomeric gp120 regimen, V2 Abs in rectal secretions, the site of viral challenge, were associated with efficacy.


Subject(s)
Antibodies, Viral/immunology , CD4 Antigens/immunology , Gene Products, env/immunology , SAIDS Vaccines/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , Viral Vaccines/immunology , Animals , CD4 Antigens/chemistry , Cell Line , Gene Products, env/chemistry , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/prevention & control
5.
Nat Med ; 22(7): 762-70, 2016 07.
Article in English | MEDLINE | ID: mdl-27239761

ABSTRACT

A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution of alum with the more immunogenic MF59 adjuvant is under consideration for the next efficacy human trial. We found here that an ALVAC-simian immunodeficiency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but not an ALVAC-SIV + gp120 MF59 vaccine, was efficacious in delaying the onset of SIVmac251 in rhesus macaques, despite the higher immunogenicity of the latter adjuvant. Vaccine efficacy was associated with alum-induced, but not with MF59-induced, envelope (Env)-dependent mucosal innate lymphoid cells (ILCs) that produce interleukin (IL)-17, as well as with mucosal IgG to the gp120 variable region 2 (V2) and the expression of 12 genes, ten of which are part of the RAS pathway. The association between RAS activation and vaccine efficacy was also observed in an independent efficacious SIV-vaccine approach. Whether RAS activation, mucosal ILCs and antibodies to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further studies.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Alum Compounds/therapeutic use , SAIDS Vaccines/therapeutic use , Simian Acquired Immunodeficiency Syndrome/prevention & control , Viral Vaccines/therapeutic use , Adaptive Immunity/immunology , Animals , Immunity, Innate/immunology , Immunity, Mucosal , Immunogenicity, Vaccine , Immunoglobulin G/immunology , Interleukin-17/immunology , Lymphocytes , Macaca mulatta , Membrane Glycoproteins/immunology , Random Allocation , Signal Transduction , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/immunology , Transcriptome , Viral Envelope Proteins/immunology , ras Proteins/immunology
6.
Lancet Infect Dis ; 14(3): 197-204, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24291168

ABSTRACT

BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) is a major cause of travellers' diarrhoea. We investigated the efficacy and safety of a skin-patch vaccine containing the pathogen's heat-labile toxin (LT) in a population of travellers to Mexico and Guatemala. METHODS: In this phase 3, randomised, double-blind, placebo-controlled field trial, healthy adults (aged 18-64 years) travelling from Germany or the UK to Mexico or Guatemala were assigned in a 1:1 ratio by a dynamic electronic randomisation system to receive transcutaneous immunisation with a patch containing 37.5 µg of ETEC LT or a placebo patch. Participants, site staff, and the investigators who did the analyses were masked to group assignment. Participants were vaccinated before travel, with two patches given 14 days apart. In the destination country, participants tracked stool output in a diary and provided stool samples for pathogen identification if diarrhoea occurred. The primary endpoint was the proportion of participants with at least one episode of moderate-to-severe diarrhoea (defined as four or more unformed stools in a 24 h period) in which either or both ETEC enterotoxins (LT and heat-stable toxin [ST]) were detected. The study is registered at ClinicalTrials.gov, number NCT00993681. FINDINGS: 2036 participants were recruited and randomly assigned between Oct 14, 2009, and Aug 13, 2010, with 1016 allocated to receive the LT patch and 1020 the placebo patch. 821 participants in the LT-patch group and 823 in the placebo group received both vaccinations and were analysed in the per-protocol population. 30 (3.7%, 95% CI 2.5-5.2) participants in the LT-patch group and 46 (5.6%, 4.1-7.4) in the placebo group had moderate or severe ETEC diarrhoea (vaccine efficacy 34.6%, -2.2 to 58.9; p=0.0621). 9333 local (ie, patch-site) adverse events (including erythema, rash, pruritus, hyperpigmentation, pain, hypopigmentation, and oedema) occurred in 943 (93%) of 1015 participants in the LT-patch group, compared with 1444 local adverse events in 574 (56%) of 1019 participants in the placebo group (p<0.0001). Serious adverse events occurred in 25 participants (14 in the LT-patch group and 11 in the placebo group), with all regarded as either unrelated or possibly related to treatment. Vaccine-induced hyperpigmentation persisted for at least 180 days after vaccination in 150 (18%) of the 849 participants who received both vaccinations and returned for final assessment in the LT-patch group, compared with none of the 842 participants in the placebo group. The vaccine was immunogenic, with a post-vaccination geometric mean titre of LT-specific serum immunoglobulin G of 3400.29, compared with 315.41 in the placebo group. INTERPRETATION: Although the LT antigen was delivered effectively by the skin patch, the vaccine did not protect travellers against diarrhoea caused by ETEC or other organisms. Future vaccines against travellers' diarrhoea might need to include several antigens against various diarrhoeal pathogens, and might need to be able to generate mucosal and higher systemic immunity.


Subject(s)
Bacterial Toxins/immunology , Diarrhea/prevention & control , Enterotoxins/immunology , Escherichia coli Proteins/immunology , Escherichia coli Vaccines/administration & dosage , Escherichia coli/immunology , Travel , Administration, Cutaneous , Adolescent , Adult , Developing Countries , Diarrhea/microbiology , Double-Blind Method , Drug Delivery Systems , Escherichia coli Vaccines/adverse effects , Europe , Female , Guatemala , Humans , Immunization/methods , Male , Mexico , Middle Aged , Young Adult
7.
Liver Transpl ; 18(6): 716-26, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22328294

ABSTRACT

Hepatitis C virus (HCV) is a controversial indication for liver transplantation (LT) in human immunodeficiency virus (HIV)-infected patients because of reportedly poor outcomes. This prospective, multicenter US cohort study compared patient and graft survival for 89 HCV/HIV-coinfected patients and 2 control groups: 235 HCV-monoinfected LT controls and all US transplant recipients who were 65 years old or older. The 3-year patient and graft survival rates were 60% [95% confidence interval (CI) = 47%-71%] and 53% (95% CI = 40%-64%) for the HCV/HIV patients and 79% (95% CI = 72%-84%) and 74% (95% CI = 66%-79%) for the HCV-infected recipients (P < 0.001 for both), and HIV infection was the only factor significantly associated with reduced patient and graft survival. Among the HCV/HIV patients, older donor age [hazard ratio (HR) = 1.3 per decade], combined kidney-liver transplantation (HR = 3.8), an anti-HCV-positive donor (HR = 2.5), and a body mass index < 21 kg/m(2) (HR = 3.2) were independent predictors of graft loss. For the patients without the last 3 factors, the patient and graft survival rates were similar to those for US LT recipients. The 3-year incidence of treated acute rejection was 1.6-fold higher for the HCV/HIV patients versus the HCV patients (39% versus 24%, log rank P = 0.02), but the cumulative rates of severe HCV disease at 3 years were not significantly different (29% versus 23%, P = 0.21). In conclusion, patient and graft survival rates are lower for HCV/HIV-coinfected LT patients versus HCV-monoinfected LT patients. Importantly, the rates of treated acute rejection (but not the rates of HCV disease severity) are significantly higher for HCV/HIV-coinfected recipients versus HCV-infected recipients. Our results indicate that HCV per se is not a contraindication to LT in HIV patients, but recipient and donor selection and the management of acute rejection strongly influence outcomes.


Subject(s)
Coinfection/mortality , Graft Rejection/mortality , Graft Survival , HIV Infections/mortality , Hepatitis C, Chronic/mortality , Liver Transplantation/mortality , Abdomen, Acute , Adult , Female , Follow-Up Studies , Humans , Incidence , Kidney Transplantation/mortality , Male , Middle Aged , Postoperative Complications/mortality , Prospective Studies , Risk Factors , Survival Analysis , Treatment Outcome , United States/epidemiology
8.
Pediatr Transplant ; 15(2): 167-71, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21199208

ABSTRACT

NAPRTCS data were analyzed to assess outcome of TX recipients from YDs (<5 yr) in comparison with IDs (6-35 yr) and ODs (36-55 yr). Of 9854 TX in NAPRTCS (1987-2003), 469 were YD. Patient survival (PS) and graft survival (GS) were compared between DD TX after 1995; 81YD, 1324 ID, and 429 OD and eGFR were compared among functioning grafts (YD 31, ID 439, OD 174) at three yr. PS was comparable in all groups; GS at one, two, and three yr in TX of YD (91.1%, 83.8%, 79.7%), ID (93.5%, 89.7%, 83.6%), and OD (92.2%, 87.2%, 82.4%) was comparable. The eGFR in YD was comparable to ID but better than OD (86.5 vs. 79.7 vs. 67.2 mL/min/1.73 m2, p 0.139 and<0.0003). Primary graft non-function was more frequent in TX from YD than ID and OD (3.7% vs. 0.3 and 0.7%, p=0.004); the incidence of vascular thrombosis was similar. The aforementioned data show that pediatric recipients of YD had equivalent patient and graft survival. Although primary graft non-function was higher, eGFR of functioning grafts was comparable to ID. With further improvements in care, kidneys from YD may present a viable option for transplantation.


Subject(s)
Kidney Transplantation/methods , Tissue Donors , Adolescent , Adult , Age Factors , Chi-Square Distribution , Child , Disease-Free Survival , Female , Follow-Up Studies , Glomerular Filtration Rate/physiology , Graft Rejection , Graft Survival , Humans , Kaplan-Meier Estimate , Kidney Function Tests , Kidney Transplantation/adverse effects , Living Donors , Male , Middle Aged , Pediatrics , Postoperative Care/methods , Registries , Retrospective Studies , Statistics, Nonparametric , Survival Analysis , Treatment Outcome , United States , Young Adult
9.
N Engl J Med ; 363(21): 2004-14, 2010 Nov 18.
Article in English | MEDLINE | ID: mdl-21083386

ABSTRACT

BACKGROUND: The outcomes of kidney transplantation and immunosuppression in people infected with human immunodeficiency virus (HIV) are incompletely understood. METHODS: We undertook a prospective, nonrandomized trial of kidney transplantation in HIV-infected candidates who had CD4+ T-cell counts of at least 200 per cubic millimeter and undetectable plasma HIV type 1 (HIV-1) RNA levels while being treated with a stable antiretroviral regimen. Post-transplantation management was provided in accordance with study protocols that defined prophylaxis against opportunistic infection, indications for biopsy, and acceptable approaches to immunosuppression, management of rejection, and antiretroviral therapy. RESULTS: Between November 2003 and June 2009, a total of 150 patients underwent kidney transplantation; survivors were followed for a median period of 1.7 years. Patient survival rates (±SD) at 1 year and 3 years were 94.6±2.0% and 88.2±3.8%, respectively, and the corresponding mean graft-survival rates were 90.4% and 73.7%. In general, these rates fall somewhere between those reported in the national database for older kidney-transplant recipients (≥65 years) and those reported for all kidney-transplant recipients. A multivariate proportional-hazards analysis showed that the risk of graft loss was increased among patients treated for rejection (hazard ratio, 2.8; 95% confidence interval [CI], 1.2 to 6.6; P=0.02) and those receiving antithymocyte globulin induction therapy (hazard ratio, 2.5; 95% CI, 1.1 to 5.6; P=0.03); living-donor transplants were protective (hazard ratio, 0.2; 95% CI, 0.04 to 0.8; P=0.02). A higher-than-expected rejection rate was observed, with 1-year and 3-year estimates of 31% (95% CI, 24 to 40) and 41% (95% CI, 32 to 52), respectively. HIV infection remained well controlled, with stable CD4+ T-cell counts and few HIV-associated complications. CONCLUSIONS: In this cohort of carefully selected HIV-infected patients, both patient- and graft-survival rates were high at 1 and 3 years, with no increases in complications associated with HIV infection. The unexpectedly high rejection rates are of serious concern and indicate the need for better immunotherapy. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00074386.).


Subject(s)
HIV Infections/complications , Immunosuppression Therapy , Kidney Failure, Chronic/surgery , Kidney Transplantation , AIDS-Related Opportunistic Infections/prevention & control , Adult , CD4 Lymphocyte Count , Chemoprevention , Female , Follow-Up Studies , Graft Rejection/epidemiology , Graft Survival , HIV Infections/immunology , Humans , Immunosuppressive Agents/therapeutic use , Kaplan-Meier Estimate , Kidney Failure, Chronic/etiology , Kidney Transplantation/immunology , Kidney Transplantation/mortality , Male , Middle Aged , Multivariate Analysis , Opportunistic Infections , Proportional Hazards Models , Transplantation, Homologous
10.
Pediatr Transplant ; 12(6): 689-95, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18179637

ABSTRACT

rhGH, widely used to optimize linear growth in children with ESRD, also modulates B-cell precursor development and may be associated with malignancy development. To determine if rhGH use in children was associated with higher risk of PTLD, we analyzed retrospectively collected data on children with CRI, on dialysis or with renal transplants in a large multi-center registry of children with ESRD. Of the 194 LPD patients currently listed in the registry, 41 were previously enrolled in the CRI registry and 18/41 (43.9%) used rhGH during their period with CRI. Among CRI patients who later received a transplant, rates of PTLD post-transplant were significantly higher among rhGH users (18/407 or 4.4%) compared to patients who never used rhGH during their CRI follow-up and received a transplant (23/1240 or 1.9%, p = 0.009). After adjusting for the confounders of recipient age (at CRI and at transplant) and transplant era, the use of rhGH pretransplant was associated with a borderline higher risk for PTLD (odds ratio 1.88, 95% CI = 1.00-3.55, p = 0.05). In contrast, use of rhGH during dialysis or post-transplant only was not associated with a higher risk for PTLD. Continued monitoring is recommended.


Subject(s)
Growth Hormone/immunology , Growth Hormone/therapeutic use , Lymphoproliferative Disorders/etiology , Adolescent , Child , Child, Preschool , Cohort Studies , Humans , Immunosuppressive Agents/therapeutic use , Infant , Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/epidemiology , Registries , Retrospective Studies , Risk , Transplantation Conditioning/methods , Treatment Outcome
11.
Pediatr Transplant ; 11(4): 366-73, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17493215

ABSTRACT

This summary of the NAPRTCS 2006 Annual Report of the Transplant Registry highlights the significant impact the registry has had in advancing knowledge in pediatric renal transplantation worldwide. This cooperative group has collected clinical information on children undergoing a renal transplantation since 1987 and now includes over 150 participating medical centers in the USA, Canada, Mexico, and Costa Rica. Currently, the NAPRTCS transplant registry includes information on 9837 renal transplants in 8990 patients (NAPRTCS 2006 Annual Report). Since the first data analysis in 1989, NAPRTCS reports have documented marked improvements in outcome after renal transplantation in addition to identifying factors associated with both favorable and poor outcomes. The registry has served to document and influence practice patterns, clinical outcomes, and changing trends in renal transplantation.


Subject(s)
Clinical Trials as Topic/statistics & numerical data , Kidney Diseases/surgery , Kidney Transplantation/trends , Registries , Societies, Medical , Adolescent , Adult , Annual Reports as Topic , Canada/epidemiology , Child , Child, Preschool , Costa Rica/epidemiology , Female , Graft Rejection/epidemiology , Humans , Incidence , Infant , Infant, Newborn , Kidney Diseases/epidemiology , Male , Mexico/epidemiology , Middle Aged , Outcome Assessment, Health Care , Retrospective Studies , Survival Rate/trends , Tissue Donors/statistics & numerical data , United States/epidemiology
12.
Pediatr Transplant ; 9(3): 282-92, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15910382

ABSTRACT

Acute rejection leading to renal graft failure is more frequent among children. In patients treated with T cell antibody induction, retrospective data from the pediatric registry show a 22% reduction in the risk of graft failure. We conducted a randomized trial (n = 287) using OKT3 mAbs in one (OKT3) arm and intravenous cyclosporine in the other arm (CYS). Maintenance therapy consisted of randomized, double blind Sandimmune or Neoral together with prednisone and either azathioprine (AZA) or mycophenolate mofetil (MMF). Morbidity, mortality, rejection rates and adverse reactions in the two study arms were similar. Through 4 yr, graft failure was 27% in OKT3 and 19% in CYS (p = 0.15). One-year graft survival was 89.1% in OKT3 and 89.2% in CYS (p = .19). In multivariate analysis, OKT3 had a numerically inferior graft survival (RR = 1.4, CI 0.8-2.2, p = 0.22). In OKT3 graft survival was inferior for children aged 6 yr or younger. Our trial demonstrates that the incidence of acute rejection or graft failure in pediatric patients is not improved by OKT3 induction therapy relative to cyclosporine induction.


Subject(s)
Cyclosporine/therapeutic use , Graft Rejection/prevention & control , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Muromonab-CD3/therapeutic use , Adolescent , Azathioprine/therapeutic use , Child , Child, Preschool , Creatinine/blood , Female , Glomerular Filtration Rate , Graft Survival/immunology , Humans , Infant , Male , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Prednisone/therapeutic use , Transplantation, Homologous , Treatment Failure
13.
J Am Soc Nephrol ; 15(11): 2923-32, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15504946

ABSTRACT

This study assessed hemodialysis adequacy in pediatric centers. Monthly adequacy data were requested in NAPRTCS enrollees on hemodialysis for at least 6 mo. Data forms were returned for 147 children from 32 centers. Data are presented for the 138 children (57% boys, 45% black) that were dialyzed 3 times/wk, representing 2282 patient-months of follow-up. Pre- and postdialysis BUN levels were reported in all children. Kt/V values were reported in 76 children; however, sufficient data were obtained to calculate Kt/V in 129 children. On average, 14.9 Kt/V and 15.2 urea reduction ratio (URR) values were calculated per child. Aggregate dialysis dose was defined as adequate if Kt/V was >1.2 in at least 75% of calculated Kt/V measures within a subject. Mean +/- SD age was 11.3 +/- 3.7 yr (median, 12.0 yr). Hemodialysis dose was variable within subjects (median CV%: URR 8.2, Kt/V 16.9). Aggregate dialysis dose was adequate in 70% of subjects. Multivariate logistic regression showed male gender (OR, 0.41; 95% CI, 0.16 to 0.98), black race (OR, 0.28; 95% CI, 0.11 to 0.67), larger body surface area (fourth versus first quartile: OR, 0.22; 95% CI, 0.05 to 0.80), and absence of reported Kt/V at the treating center (OR, 0.26; 95% CI, 0.10 to 0.62) were significant predictors of inadequate dialysis dose. Age, renal diagnosis, and center size were not associated with adequacy. Racial and gender disparities in hemodialysis dose existed among children at specialized academic pediatric centers and a substantial proportion received inadequate hemodialysis.


Subject(s)
Black People , Hospitals, Pediatric , Quality of Health Care , Renal Dialysis/standards , Socioeconomic Factors , Adolescent , Body Surface Area , Canada , Child , Child, Preschool , Confidence Intervals , Female , Humans , Infant , Logistic Models , Male , Sex Factors , United States , Urea/metabolism
14.
Am J Transplant ; 4(3): 384-9, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14961991

ABSTRACT

Newer immunosuppressive agents have dramatically reduced the rates of acute graft rejection (AR) over the last decade but may have exacerbated the problem of post-transplant infections (PTI). We analyzed data from the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) to determine the risks of hospitalization from PTI vs. AR in the years 1987-2000. For patients transplanted in 1987, the AR-associated hospitalization rate exceeded the equivalent hospitalization rate for PTI at both early (1-6 months) and later time points (6-24 months). In contrast, for patients transplanted in the year 2000, the PTI-associated hospitalization rate was twice that for AR-associated hospitalization during each time period. During the first two years post-transplant, rates of AR hospitalization trended significantly downwards (p < 0.001) while rates of PTI-associated hospitalization stayed constant. In the 6-24-month time period post-transplant, the risk of bacterial and viral infection-related hospitalization rose significantly from 1987 to 2000 (p < 0.001 for trend by transplant year). We conclude that the causes of hospitalization at all times up to 24 months post-transplant, including the critical early 6 months, have shifted away from AR to PTI.


Subject(s)
Communicable Diseases/epidemiology , Graft Rejection/epidemiology , Hospitalization/statistics & numerical data , Opportunistic Infections/epidemiology , Transplantation , Child , Child, Preschool , Female , Hospitalization/trends , Humans , Infant , Male , Mycoses/epidemiology , Time Factors
15.
Pediatr Transplant ; 6(5): 396-9, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12390426

ABSTRACT

Tacrolimus (FK506) and mycophenolate mofetil (MMF) have been reported to increase PTLD risk. The NAPRTCS registry database now has several years of data on FK506 and MMF use in pediatric kidney transplantation. We analyzed the data registry to determine if the risk of PTLD was enhanced by the use of MMF or tacrolimus in initial immunosuppression. Data on day 30 therapy in the PTLD group were compared to corresponding data in patients who did not develop PTLD. Data were analyzed using SAS software and a log-rank test for significance. As of October 2000, there were 108 cases of PTLD in 6720 total transplants(1.60%). The use of MMF at day 30 was not a significant risk factor (0. 78% PTLD rate vs. 1.78% in cohort, RR = 1.05, p = 0.89). The relationship of FK506 with PTLD was linked to transplant era, 1987-95 or 1996-2000. In the earlier era, use of FK506 at day 30 was associated with PTLD (seen in 7/15 patients given FK506, RR = 47.7, p < 0.001). However, in the more recent era, there was no such significant association (seen in 3/313 patients given FK506, RR = 1.28, p = 0.692). There have been no cases of PTLD in 197 patients who received both FK506 and MMF at day 30. We conclude that FK506 and MMF use are not currently associated with increased risk of PTLD in pediatric kidney transplants.


Subject(s)
Immunosuppressive Agents/adverse effects , Kidney Transplantation , Lymphoproliferative Disorders/chemically induced , Mycophenolic Acid/adverse effects , Tacrolimus/adverse effects , Female , Humans , Kidney Transplantation/immunology , Male , Multicenter Studies as Topic , Mycophenolic Acid/analogs & derivatives
16.
Clin Transplant ; 16(5): 317-24, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12225426

ABSTRACT

BACKGROUND: The safety and immune tolerance potential of donor marrow infusion with cadaveric source renal transplants was evaluated in a series of non-randomized multicenter pilot trials by the NIH Cooperative Clinical Trials in Transplantation (CCTT) Group. PATIENTS AND METHODS: Three strategies were tested: (1) immunosuppression with cyclosporin, azathioprine and prednisone with a single post-transplant day 1 infusion of 5 x 107 viable cells/kg, (2) OKT3 induction with triple drug therapy and marrow transfusion on day 1, or (3) same therapy as (2) but with an additional marrow transfusion on day 10-12. RESULTS: Thirty-eight marrow recipients and 35 contemporaneous controls were entered with a mean follow-up of over 5 yr. Graft survival was initially better in the marrow recipients than the controls but was similar after 5 yr. Microchimerism rates were similar for the marrow infusion and control groups throughout the follow-up period, regardless of the immunosuppression strategies. DISCUSSION: Bone marrow infusions were well tolerated by a group of cadaver renal allograft recipients. There were no complications from the infusion(s), no episodes of graft-vs.-host disease (GVHD) and no increase in infections or other complications. There was a trend toward early improved graft survival in marrow recipients. Decreased rejection rates were observed in black recipients.


Subject(s)
Bone Marrow Transplantation , Kidney Transplantation/immunology , Cadaver , Clinical Protocols , Clinical Trials as Topic , Graft Rejection/immunology , Humans , Immune Tolerance , Immunosuppressive Agents/therapeutic use , Multicenter Studies as Topic , Muromonab-CD3/therapeutic use , Retrospective Studies , Transplantation Chimera , Transplantation, Homologous
17.
Am J Transplant ; 2(2): 142-7, 2002 Feb.
Article in English | MEDLINE | ID: mdl-12099516

ABSTRACT

Chronic rejection accounted for 32% of all graft losses in 7123 pediatric transplants. In a previous study acute, multiple acute and late acute rejections were risk factors for the development of chronic rejection. We postulated that the recent decrease in acute rejections would translate into a lower risk for chronic rejection among patients with recent transplants. We reviewed our data on patients transplanted from 1995 to 2000, and using multivariate analysis and a proportional hazards model developed risk factors for patients whose grafts had failed due to chronic rejection. A late initial rejection increased the risk of chronic rejection graft failure 3.6-fold (p < 0.001), while a second rejection resulted in further increase of 4.2-fold (p < 0.001). Recipients who received less than 5 mg/kg of cyclosporine at 30 days post-transplant had a relative risk (RR) of 1.9 (p = 0.02). Patients transplanted from 1995 to 2000 had a significantly lower risk (RR = 0.54, p < 0.001) of graft failure from chronic rejection than those who received their transplants earlier (1987-94). Since we were able to demonstrate that there is a decreased risk of chronic rejection graft failure in our study cohort, we would conclude that the goal of future transplants should be to minimize acute rejections.


Subject(s)
Graft Rejection/prevention & control , Kidney Transplantation/immunology , Acute Disease , Analysis of Variance , Cadaver , Child , Child, Preschool , Chronic Disease , Cohort Studies , Female , Humans , Kidney Diseases/epidemiology , Living Donors , Male , Multivariate Analysis , Postoperative Complications/epidemiology , Racial Groups , Reoperation , Retrospective Studies , Time Factors , Tissue Donors , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...